Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah E Pinder

Showing results (51-60 of 149) with videos related to

Pageof 15
Sort By:
Cancer Immunology, Immunotherapy : CII|September 21, 2004
Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?Zahra Madjd, Lindy G Durrant, Sarah E Pinder, et al.
Cancer Immunity|October 24, 2007
Upregulation of MICA on high-grade invasive operable breast carcinomaZahra Madjd, Ian Spendlove, Robert Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized TrialMangesh A Thorat, Pauline M Levey, J Louise Jones, et al.
Heliyon|March 21, 2024
Translating microcalcification biomarker information into the laboratory: A preliminary assessment utilizing core biopsies obtained from sites of mammographic calcificationIain D Lyburn, Robert Scott, Eleanor Cornford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma <i>in situ</i>: Results from the UK/ANZ DCIS TrialMangesh A Thorat, Pauline M Levey, J Louise Jones, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 28, 2010
An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelinesAnthony O'Grady, David Allen, Lisa Happerfield, et al.
Histopathology|May 13, 2010
Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breastZsolt Hodi, Ian O Ellis, Christopher W Elston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?Raj S Rampaul, Sarah E Pinder, Pete M Wencyk, et al.
The American Journal of Surgical Pathology|December 28, 2002
Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinomaGavin C Harris, Helen E Denley, Sarah E Pinder, et al.
Histopathology|December 29, 2016
Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance SchemeEmad A Rakha, Mohamed A Ahmed, Mohammed A Aleskandarany, et al.
Pageof 15

Showing results (51-60 of 149) with videos related to

Sort By:
Pageof 15
Cancer Immunology, Immunotherapy : CII|September 21, 2004
Do poor-prognosis breast tumours express membrane cofactor proteins (CD46)?Zahra Madjd, Lindy G Durrant, Sarah E Pinder, et al.
Cancer Immunity|October 24, 2007
Upregulation of MICA on high-grade invasive operable breast carcinomaZahra Madjd, Ian Spendlove, Robert Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ: Results from the UK/ANZ DCIS Randomized TrialMangesh A Thorat, Pauline M Levey, J Louise Jones, et al.
Heliyon|March 21, 2024
Translating microcalcification biomarker information into the laboratory: A preliminary assessment utilizing core biopsies obtained from sites of mammographic calcificationIain D Lyburn, Robert Scott, Eleanor Cornford, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma <i>in situ</i>: Results from the UK/ANZ DCIS TrialMangesh A Thorat, Pauline M Levey, J Louise Jones, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|July 28, 2010
An immunohistochemical and fluorescence in situ hybridization-based comparison between the Oracle HER2 Bond Immunohistochemical System, Dako HercepTest, and Vysis PathVysion HER2 FISH using both commercially validated and modified ASCO/CAP and United Kingdom HER2 IHC scoring guidelinesAnthony O'Grady, David Allen, Lisa Happerfield, et al.
Histopathology|May 13, 2010
Comparison of margin assessment by radial and shave sections in wide local excision specimens for invasive carcinoma of the breastZsolt Hodi, Ian O Ellis, Christopher W Elston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2004
Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?Raj S Rampaul, Sarah E Pinder, Pete M Wencyk, et al.
The American Journal of Surgical Pathology|December 28, 2002
Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinomaGavin C Harris, Helen E Denley, Sarah E Pinder, et al.
Histopathology|December 29, 2016
Diagnostic concordance of breast pathologists: lessons from the National Health Service Breast Screening Programme Pathology External Quality Assurance SchemeEmad A Rakha, Mohamed A Ahmed, Mohammed A Aleskandarany, et al.
Pageof 15